GRIN-NDD

R&D

Dr Bruce Leuchter, CEO of GRIN Therapeutics and Neurvati Neurosciences, discusses the companies GRIN-NDD work with pharmaphorum.

Oncology

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.